HLB Pharmaceutical Co. Ltd (047920) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.015x

Based on the latest financial reports, HLB Pharmaceutical Co. Ltd (047920) has a cash flow conversion efficiency ratio of 0.015x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩1.86 Billion ≈ $1.26 Million USD) by net assets (₩120.95 Billion ≈ $81.97 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

HLB Pharmaceutical Co. Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)

This chart illustrates how HLB Pharmaceutical Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read HLB Pharmaceutical Co. Ltd debt and liabilities for a breakdown of total debt and financial obligations.

HLB Pharmaceutical Co. Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of HLB Pharmaceutical Co. Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Shanghai KEN Tools Co Ltd SHE:300126	-0.029x
Shenzhen Maxonic Auto Control SHE:300112	0.015x
Gigastorage Corp TW:2406	-0.002x
Lingnan Landscape Co Ltd SHE:002717	-0.002x
Hellenic Exchanges - Athens Stock Exchange SA AT:EXAE	0.162x
Oyak Yatirim Menkul Degerler AS IS:OYYAT	-0.010x
Regulus Resources Inc V:REG	-0.015x
IMC SA WAR:IMC	0.075x

Annual Cash Flow Conversion Efficiency for HLB Pharmaceutical Co. Ltd (2014–2024)

The table below shows the annual cash flow conversion efficiency of HLB Pharmaceutical Co. Ltd from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see 047920 market cap overview.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩116.40 Billion ≈ $78.88 Million	₩6.84 Billion ≈ $4.64 Million	0.059x	+128.28%
2023-12-31	₩88.15 Billion ≈ $59.74 Million	₩-18.32 Billion ≈ $-12.41 Million	-0.208x	-546.24%
2022-12-31	₩85.93 Billion ≈ $58.23 Million	₩-2.76 Billion ≈ $-1.87 Million	-0.032x	-90.74%
2021-12-31	₩78.38 Billion ≈ $53.12 Million	₩-1.32 Billion ≈ $-895.45K	-0.017x	-86.48%
2020-12-31	₩44.62 Billion ≈ $30.24 Million	₩-403.36 Million ≈ $-273.35K	-0.009x	-111.60%
2019-12-31	₩17.36 Billion ≈ $11.76 Million	₩1.35 Billion ≈ $917.12K	0.078x	+174.56%
2018-12-31	₩17.00 Billion ≈ $11.52 Million	₩-1.78 Billion ≈ $-1.20 Million	-0.105x	-124.00%
2017-12-31	₩16.80 Billion ≈ $11.39 Million	₩-784.30 Million ≈ $-531.51K	-0.047x	-313.95%
2016-12-31	₩18.90 Billion ≈ $12.81 Million	₩-213.11 Million ≈ $-144.42K	-0.011x	+82.16%
2015-12-31	₩12.18 Billion ≈ $8.25 Million	₩-769.59 Million ≈ $-521.54K	-0.063x	-119.72%
2014-12-31	₩4.81 Billion ≈ $3.26 Million	₩1.54 Billion ≈ $1.05 Million	0.320x	--

About HLB Pharmaceutical Co. Ltd

KQ:047920 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$364.53 Million

₩537.90 Billion KRW

Market Cap Rank

#14169 Global

#489 in Korea

Share Price

₩16400.00

Change (1 day)

-2.09%

52-Week Range

₩13040.00 - ₩20900.00

All Time High

₩41100.00